UNITY Biotechnology, Inc. reported its financial results for the first quarter of 2025, highlighting the 24-week and partial 36-week topline data from its Phase 2b ASPIRE study in diabetic macular ...

SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UBX) (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases ...

UNITY Biotechnology (NASDAQ:UBX) stock fell 30% after the company's mid-stage trial for its diabetic macular edema treatment did not meet main goal. The study showed that patients treated with UBX1325 ...

UNITY Biotechnology has appointed Federico Grossi, M.D., Ph.D., as its new chief medical officer to enhance its leadership team. Dr. Grossi, who has over 20 years of experience in biotech, previously ...

(KRON) — The future of one biotech company on the Peninsula is drastically changing. Unity Biotechnology is laying off its entire workforce, the company announced Monday in a press release. The ...

This press release contains forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY ...

SAN FRANCISCO, March 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today ...

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Unity Biotechnology (UBX – Research Report), with a price target of $10.00. The company’s shares opened ...

Unity Biotechnology, Inc. (NASDAQ:UBX) stock plummeted on Monday after the company released results from its latest study. The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients ...